Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mast Therapeutics Inc (NYSE MKT LLC:MSTX)

0.1221
Delayed Data
As of Dec 09
 +0.0031 / +2.61%
Today’s Change
0.07
Today|||52-Week Range
0.71
-70.95%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$29.1M

Company Description

Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA.

Contact Information

Mast Therapeutics, Inc.
3611 Valley Centre Drive
San Diego California 92130
P:(858) 552-0866
Investor Relations:
18585520866303

Employees

Shareholders

Other institutional6.45%
Mutual fund holders5.26%
Individual stakeholders0.22%

Top Executives

Brian M. CulleyChief Executive Officer & Director
Brandi L. RobertsCFO, Principal Accounting Officer & SVP
Edwin L. ParsleyChief Medical Officer & Senior Vice President
Shana C. HoodSecretary, Vice President & General Counsel
Robert Martin EmanueleSenior Vice President-Development